Sam Brusco, Associate Editor04.04.23
Sight Sciences, an eyecare technology company, has appointed Alison “Ali” Bauerlein as its new chief financial officer (CFO) and treasurer, effective April 3.
Bauerlein comes to Sight Sciences from Inogen, a homecare respiratory products maker. She co-founded Inogen in 2001 and was the company’s CFO from 2009 through 2021. Bauerlein has also been a member of the board of directors of software-based digital therapeutics company Pear Therapeutics since December 2021, as well as a board member for biotherapeutics company Gelesis Holdings since 2022.
Bauerlein has also been a board member for private company Koya Medical since January 2021.
“I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will provide an immediate and valuable impact,” Paul Badawi, co-founder and CEO of Sight Sciences told the press. “A proven entrepreneur and executive, Ali will partner with our team to advance our strategic plan and ensure we have the appropriate financial infrastructure to support our growth. I would like to thank Jim Rodberg for his ever-increasing leadership and commitment to our mission as he stepped into the interim Chief Financial Officer and Treasurer role and managed the finance organization exceptionally well.”
Bauerlein added, “Sight Sciences is a leader in eyecare technology innovation with a portfolio and pipeline of products disrupting two distinct multibillion dollar markets and generating top-tier revenue growth. I have firsthand experience with this stage of transformational growth and development and am excited to leverage my background in high growth medtech to help Sight Sciences achieve its fullest potential. I look forward to working with Paul and the Sight Sciences team to support our current growth and profitability plans, while improving the lives of our patients and striving to create maximum value for the ophthalmic community and our stockholders.”
Bauerlein comes to Sight Sciences from Inogen, a homecare respiratory products maker. She co-founded Inogen in 2001 and was the company’s CFO from 2009 through 2021. Bauerlein has also been a member of the board of directors of software-based digital therapeutics company Pear Therapeutics since December 2021, as well as a board member for biotherapeutics company Gelesis Holdings since 2022.
Bauerlein has also been a board member for private company Koya Medical since January 2021.
“I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will provide an immediate and valuable impact,” Paul Badawi, co-founder and CEO of Sight Sciences told the press. “A proven entrepreneur and executive, Ali will partner with our team to advance our strategic plan and ensure we have the appropriate financial infrastructure to support our growth. I would like to thank Jim Rodberg for his ever-increasing leadership and commitment to our mission as he stepped into the interim Chief Financial Officer and Treasurer role and managed the finance organization exceptionally well.”
Bauerlein added, “Sight Sciences is a leader in eyecare technology innovation with a portfolio and pipeline of products disrupting two distinct multibillion dollar markets and generating top-tier revenue growth. I have firsthand experience with this stage of transformational growth and development and am excited to leverage my background in high growth medtech to help Sight Sciences achieve its fullest potential. I look forward to working with Paul and the Sight Sciences team to support our current growth and profitability plans, while improving the lives of our patients and striving to create maximum value for the ophthalmic community and our stockholders.”